NOT-TR-23-012: Notice of Termination of RFA-TR-22-011 HEAL Initiative-Early-Stage Discovery of New Pain and Opioid Use Disorder Targets Within the Understudied Druggable Proteome (R21)

Notice of Termination of RFA-TR-22-011 HEAL Initiative-Early-Stage Discovery of New Pain and Opioid Use Disorder Targets Within the Understudied Druggable Proteome (R21)

Notice Number:

NOT-TR-23-012

Key Dates

Release Date:

April 17, 2023

Related Announcements

RFA-TR-22-011 - "Emergency Awards: HEAL Initiative-Early-Stage Discovery of New Pain and Opioid Use Disorder Targets Within the Understudied Druggable Proteome (R21 Clinical Trial Not Allowed)

RFA-TR-23-010 - Emergency Awards: HEAL Initiative-Early-Stage Discovery of New Pain and Opioid Use Disorder Targets Within the Understudied Druggable Proteome (R21 Clinical Trial Not Allowed)

Issued by

National Center for Advancing Translational Sciences (NCATS)

National Institute on Aging (NIA)

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

National Institute of Neurological Disorders and Stroke (NINDS)

Purpose

Effective immediately, the Funding Opportunity Announcement RFA-TR-22-011 "Emergency Awards: HEAL Initiative-Early-Stage Discovery of New Pain and Opioid Use Disorder Targets Within the Understudied Druggable Proteome (R21 Clinical Trial Not Allowed) is terminated. Applications submitted to RFA-TR-22-011 will not be reviewed. NIH has reissued this Funding Opportunity Announcement as RFA-TR-23-010 "Emergency Awards: HEAL Initiative-Early-Stage Discovery of New Pain and Opioid Use Disorder Targets Within the Understudied Druggable Proteome (R21 Clinical Trial Not Allowed)

Inquiries

Please direct all inquiries to:

Karlie Sharma, Ph.D.
National Center for Advancing Translational Sciences (NCATS)
Telephone: 301-451-4965
Email: [email protected]